SCHEMBL17997146

SCHEMBL17997146

CCCC(C)S(=O)(=O)c1nnnn1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.52
MAPT P10636 8/20 0.52
NPSR1 Q6W5P4 5/20 0.48
LMNA P02545 5/20 0.48
TP53 P04637 5/20 0.48
HTT P42858 4/20 0.48
HSD17B10 Q99714 3/20 0.48
HPGD P15428 3/20 0.48
KMT2A Q03164 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
S1PR4 O95977 2/20 0.44
S1PR1 P21453 2/20 0.44
RAB9A P51151 2/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 3/20 0.40
PTGS2 P35354 1/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13344784 0.82 ALDH1A1 (0.56) ALDH1A1MAPTNPSR1LMNATP53
SCHEMBL19824603 0.80 ALDH1A1 (0.43) ALDH1A1MAPTNPSR1LMNATP53
SCHEMBL1710001 0.78 ALDH1A1 (0.52) ALDH1A1MAPTNPSR1LMNATP53
SCHEMBL2978401 0.77 ALDH1A1 (0.71) ALDH1A1MAPTNPSR1LMNATP53
SCHEMBL2976178 0.77 ALDH1A1 (0.69) ALDH1A1MAPTNPSR1LMNATP53
SCHEMBL2966537 0.74 ALDH1A1 (0.64) ALDH1A1MAPTNPSR1LMNATP53
SCHEMBL12443641 0.74 MAPT (0.69) ALDH1A1MAPTNPSR1LMNATP53
SCHEMBL16162343 0.73 ALDH1A1 (0.65) ALDH1A1MAPTNPSR1LMNATP53
SCHEMBL17907323 0.73 ALDH1A1 (0.38) ALDH1A1MAPTNPSR1LMNATP53
SCHEMBL17511740 0.73 ALDH1A1 (0.63) ALDH1A1MAPTNPSR1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180028509-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-02-01 US disclosed
US-9861620-B2 Substituted quinolizine derivatives useful as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2018-01-09 US disclosed
US-20160228419-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228419-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS NQO2, CYP3A5, QTRT1 ALDH1A1 1564/4885MAPT 3742/4885NPSR1 2588/4885
US-20180028509-A1 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS NQO2, CYP3A5, QTRT1 ALDH1A1 1564/4885MAPT 3742/4885NPSR1 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.